Cargando…
The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
INTRODUCTION: Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs), and tocilizumab is often used early in the treatment paradigm. Weight gain, which is associated with morbidity and mortality, is a major concern for patients, though the factors that contribu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964534/ https://www.ncbi.nlm.nih.gov/pubmed/34954809 http://dx.doi.org/10.1007/s40744-021-00411-y |
_version_ | 1784678242242789376 |
---|---|
author | Patel, Naomi J. Fu, Xiaoqing Zhang, Yuqing Unizony, Sebastian H. Wallace, Zachary S. Choi, Hyon K. Stone, John H. |
author_facet | Patel, Naomi J. Fu, Xiaoqing Zhang, Yuqing Unizony, Sebastian H. Wallace, Zachary S. Choi, Hyon K. Stone, John H. |
author_sort | Patel, Naomi J. |
collection | PubMed |
description | INTRODUCTION: Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs), and tocilizumab is often used early in the treatment paradigm. Weight gain, which is associated with morbidity and mortality, is a major concern for patients, though the factors that contribute to changes in body mass index (BMI) throughout the treatment of GCA are poorly understood. METHODS: We analyzed GCA patients enrolled in the GiACTA (Tocilizumab in Giant Cell Arteritis) trial. We used univariable and multivariable mixed-effects modeling to examine the association between changes in BMI and cumulative GC dose, disease status at baseline (newly diagnosed versus relapsing), randomization to tocilizumab, and disease flares. RESULTS: A total of 250 patients were included (75% females, mean age 69 years). The mean ± SD BMI change over 52 weeks was 1.18 ± 1.98 kg/m(2). On multivariable analysis, cumulative prednisone dose at 52 weeks was independently associated with BMI increase (β = 0.94 kg/m(2) for 0–1 g exposure; β = 1.40 kg/m(2) for ≥ 4 g exposure; p for trend < 0.001). Relapsing disease at baseline (β = − 0.42 kg/m(2) compared to those with newly diagnosed disease; p = 0.002) and flares over 52 weeks in newly diagnosed patients (β = − 0.18 kg/m(2) per flare; p = 0.03) were independently associated with lower BMI increase. CONCLUSIONS: Cumulative prednisone exposure is associated with increased BMI in GCA patients. In those with newly diagnosed disease, effective disease control regardless of the treatment used also contributes to BMI increase. Modest weight gain may be an indicator of adequate treatment response. |
format | Online Article Text |
id | pubmed-8964534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-89645342022-04-07 The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial Patel, Naomi J. Fu, Xiaoqing Zhang, Yuqing Unizony, Sebastian H. Wallace, Zachary S. Choi, Hyon K. Stone, John H. Rheumatol Ther Original Research INTRODUCTION: Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs), and tocilizumab is often used early in the treatment paradigm. Weight gain, which is associated with morbidity and mortality, is a major concern for patients, though the factors that contribute to changes in body mass index (BMI) throughout the treatment of GCA are poorly understood. METHODS: We analyzed GCA patients enrolled in the GiACTA (Tocilizumab in Giant Cell Arteritis) trial. We used univariable and multivariable mixed-effects modeling to examine the association between changes in BMI and cumulative GC dose, disease status at baseline (newly diagnosed versus relapsing), randomization to tocilizumab, and disease flares. RESULTS: A total of 250 patients were included (75% females, mean age 69 years). The mean ± SD BMI change over 52 weeks was 1.18 ± 1.98 kg/m(2). On multivariable analysis, cumulative prednisone dose at 52 weeks was independently associated with BMI increase (β = 0.94 kg/m(2) for 0–1 g exposure; β = 1.40 kg/m(2) for ≥ 4 g exposure; p for trend < 0.001). Relapsing disease at baseline (β = − 0.42 kg/m(2) compared to those with newly diagnosed disease; p = 0.002) and flares over 52 weeks in newly diagnosed patients (β = − 0.18 kg/m(2) per flare; p = 0.03) were independently associated with lower BMI increase. CONCLUSIONS: Cumulative prednisone exposure is associated with increased BMI in GCA patients. In those with newly diagnosed disease, effective disease control regardless of the treatment used also contributes to BMI increase. Modest weight gain may be an indicator of adequate treatment response. Springer Healthcare 2021-12-25 /pmc/articles/PMC8964534/ /pubmed/34954809 http://dx.doi.org/10.1007/s40744-021-00411-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Patel, Naomi J. Fu, Xiaoqing Zhang, Yuqing Unizony, Sebastian H. Wallace, Zachary S. Choi, Hyon K. Stone, John H. The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial |
title | The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial |
title_full | The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial |
title_fullStr | The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial |
title_full_unstemmed | The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial |
title_short | The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial |
title_sort | effects of treatment on body mass index in giant cell arteritis: a post hoc analysis of the giacta trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964534/ https://www.ncbi.nlm.nih.gov/pubmed/34954809 http://dx.doi.org/10.1007/s40744-021-00411-y |
work_keys_str_mv | AT patelnaomij theeffectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT fuxiaoqing theeffectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT zhangyuqing theeffectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT unizonysebastianh theeffectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT wallacezacharys theeffectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT choihyonk theeffectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT stonejohnh theeffectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT patelnaomij effectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT fuxiaoqing effectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT zhangyuqing effectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT unizonysebastianh effectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT wallacezacharys effectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT choihyonk effectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial AT stonejohnh effectsoftreatmentonbodymassindexingiantcellarteritisaposthocanalysisofthegiactatrial |